search
Back to results

Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy

Primary Purpose

Urinary Incontinence

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Burch urethropexy
Synthetic mid-urethral sling (TVT)
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Incontinence

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. older than 21 years of age;
  2. with symptomatic pelvic organ prolapse (POP-Q point Aa or C at ≥ -1 cm;
  3. who have opted for sacral colpopexy repair of prolapse;
  4. who have symptomatic SUI desiring surgical correction or who have occult SUI;
  5. who have urethral hypermobility;
  6. with a maximal cystometric capacity ≥ 200 cc;
  7. who are willing to return for follow-up visit; or
  8. who understand and have signed written informed consent to undergo randomization and who has given investigators permission to collect data pertaining to surgical care and follow-up.

Exclusion Criteria:

  1. with known or suspected disease that affect bladder function (i.e., multiple sclerosis, Parkinson's Disease, spinal cord injury, etc.);
  2. who are pregnant by self report or by positive pregnancy test;
  3. who desire to maintain fertility;
  4. with history of urethral diverticulum;
  5. with a history of radical pelvic surgery or pelvic radiation therapy;
  6. who are deemed medically poor candidates for abdominal surgery;
  7. Non-ambulatory (including those who ambulate with assistance; or
  8. who are actively undergoing chemotherapy or radiation treatment for malignancy.

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Burch

Mid-urethral sling

Arm Description

Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.

Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.

Outcomes

Primary Outcome Measures

The primary endpoint is to compare the proportion of patients who are continent in each group. Continence requires negative standardized stress test performed by a masked observer; no interim re-treatment for SUI; no self reported incontinence (ISI =0)

Secondary Outcome Measures

The secondary endpoint is to compare the proportion of patients who have stress specific continence in each group. Stress specific continence requires: fulfilling criteria 1 and 2 above and 3) no self reported SUI specific symptoms.
To compared continence, stress specific continence and patient satisfaction between groups at 12 and 24 months.
Compare the safety of the Burch and the mid-urethral sling.

Full Information

First Posted
July 6, 2009
Last Updated
August 9, 2023
Sponsor
Mayo Clinic
Collaborators
Spectrum Health Hospitals, Saint Luke's Health System
search

1. Study Identification

Unique Protocol Identification Number
NCT00934999
Brief Title
Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy
Official Title
A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
Spectrum Health Hospitals, Saint Luke's Health System

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
I. Specific Aims Pelvic organ prolapse is a common and distressing condition that is frequently associated with stress urinary incontinence (SUI) and often requires surgical repair. Abdominal sacral colpopexy is the preferred operation for repairing pelvic prolapse. As many as 91% of women with pelvic organ prolapse undergoing sacral colpopexy also experience SUI. In addition, up to 44% of previously continent women develop SUI incontinence after sacral colpopexy: perhaps because a sacral colpopexy may predispose to opening of the bladder neck if secured too tightly. The selection of a surgical procedure to prevent and manage SUI in women undergoing sacral colpopexy is empiric rather than evidence-based. Conceptually, a mid-urethral sling may be more effective than a Burch procedure for preventing urinary leakage because a sling provides outlet resistance beyond the bladder neck and therefore it may compensate for a downward tension on the bladder neck resulting from the sacral colpopexy. Indeed, clinical observations suggest that a mid-urethral sling is effective among women who have persistent urinary incontinence after sacral colpopexy with a Burch procedure. Therefore, the investigators' global hypothesis is that a mid-urethral sling is preferable to a Burch procedure for preventing and improving stress urinary incontinence in women undergoing sacral colpopexy for pelvic organ prolapse. The investigators' SPECIFIC AIMS are to evaluate objective and subjective outcomes at 6, 12 and 24 months in 124 women with urinary incontinence and advanced pelvic organ prolapse. All women will be undergoing a sacral colpopexy and will be randomized to either a Burch procedure or a mid-urethral sling. The primary endpoint is composite continence at 6 months while secondary endpoints will include composite continence and subjective measures of incontinence, patient satisfaction and morbidity associated with these procedures. The investigators' hypotheses are as follows: At 6 months, urinary continence rates will be higher after a mid-urethral than after a Burch procedure. Urine continence will be assessed by composite measure of incontinence: no subjective complaint, no interim treatment, and negative standardized stress test performed by a masked observer. This assessment will be repeated at 12 and 24 months post-operatively to establish the medium term continence of the two procedures. Subjective continence and patient satisfaction measures will be obtained at each of the above visits using standardized questionnaires and pelvic organ support will be quantified by Pelvic Organ Prolapse-Quantification (POP-Q) scores. Early events (e.g., blood loss, operative time, intra-operative complications (vascular, bowel and urological injuries), in-hospital complications (need for transfusion, febrile morbidity, thrombotic events, wound infection, length of stay, duration of bladder catheterization and ileus) and delayed postoperative complications (e.g., wound infection, mesh erosion, bowel obstruction and obstructed voiding) will be collected to compare the safety of each procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
113 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Burch
Arm Type
Active Comparator
Arm Description
Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
Arm Title
Mid-urethral sling
Arm Type
Experimental
Arm Description
Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
Intervention Type
Procedure
Intervention Name(s)
Burch urethropexy
Intervention Description
Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
Intervention Type
Procedure
Intervention Name(s)
Synthetic mid-urethral sling (TVT)
Other Intervention Name(s)
TVT
Intervention Description
Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
Primary Outcome Measure Information:
Title
The primary endpoint is to compare the proportion of patients who are continent in each group. Continence requires negative standardized stress test performed by a masked observer; no interim re-treatment for SUI; no self reported incontinence (ISI =0)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
The secondary endpoint is to compare the proportion of patients who have stress specific continence in each group. Stress specific continence requires: fulfilling criteria 1 and 2 above and 3) no self reported SUI specific symptoms.
Time Frame
6 months
Title
To compared continence, stress specific continence and patient satisfaction between groups at 12 and 24 months.
Time Frame
12 and 24 months
Title
Compare the safety of the Burch and the mid-urethral sling.
Time Frame
6, 12 and 24 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: older than 21 years of age; with symptomatic pelvic organ prolapse (POP-Q point Aa or C at ≥ -1 cm; who have opted for sacral colpopexy repair of prolapse; who have symptomatic SUI desiring surgical correction or who have occult SUI; who have urethral hypermobility; with a maximal cystometric capacity ≥ 200 cc; who are willing to return for follow-up visit; or who understand and have signed written informed consent to undergo randomization and who has given investigators permission to collect data pertaining to surgical care and follow-up. Exclusion Criteria: with known or suspected disease that affect bladder function (i.e., multiple sclerosis, Parkinson's Disease, spinal cord injury, etc.); who are pregnant by self report or by positive pregnancy test; who desire to maintain fertility; with history of urethral diverticulum; with a history of radical pelvic surgery or pelvic radiation therapy; who are deemed medically poor candidates for abdominal surgery; Non-ambulatory (including those who ambulate with assistance; or who are actively undergoing chemotherapy or radiation treatment for malignancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emanuel C. Trabuco, MD, MS
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
29215517
Citation
Trabuco EC, Linder BJ, Klingele CJ, Blandon RE, Occhino JA, Weaver AL, McGree ME, Gebhart JB. Two-Year Results of Burch Compared With Midurethral Sling With Sacrocolpopexy: A Randomized Controlled Trial. Obstet Gynecol. 2018 Jan;131(1):31-38. doi: 10.1097/AOG.0000000000002415.
Results Reference
derived

Learn more about this trial

Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy

We'll reach out to this number within 24 hrs